Ervebo Vaccines
Dec 24, 2019
Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy
Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion. Roche has agreed to license in Sarepta’s gene therapy ‘SRP-9001’ for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive rights to it globally except in the US. As per t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
